Abiopharma

🔍 Casdin Capital, LLC (Director)

Company: GeneDx Holdings Corp. (WGS)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 500,000 shares of Cash Settled Swap (Derivative)
  Date: 2026-05-07 | Code: P | equity_swap_involved: 1 | shares_owned_after: 500,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Acquired 300,000 shares of Cash Settled Swap (Derivative)
  Date: 2026-05-08 | Code: P | equity_swap_involved: 1 | shares_owned_after: 800,000.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F2
• Acquired 50,000 shares of Cash Settled Swap (Derivative)
  Date: 2026-05-11 | Code: P | equity_swap_involved: 1 | shares_owned_after: 850,000.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F2

Footnotes:

• F1: Casdin Partners Master Fund, L.P. (the "Master Fund") has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 500,000 notional shares of the Issuer's Class A Common Stock, at a price of $38.1543 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements.
• F2: The Swap Agreements are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
• F3: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 300,000 notional shares of the Issuer's Class A Common Stock, at a price of $41.0261 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements.
• F4: The Master Fund has entered into certain cash-settled swap agreements (the "Swap Agreements"), which represent economic exposure to an aggregate of 50,000 notional shares of the Issuer's Class A Common Stock, at a price of $39.6602 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements.
• REMARKS: Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.